Business
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n §  Phase 2 Study NLC-V-01 closed early after interim data analysis due to positive clinical efficacy §  Primary endpoint of time to clinical improvement reached with average reduction of 2.7 days in the Tollovir group vs. the placebo group §  0% COVID-related deaths in Tollovir™ group vs. 22% COVID-related deaths in placebo group §  Lead clinical site Shaare Zedek Medical Center now permits the use of Tollovir™ in hospitalized COVID-19 patients on a compassionate use basis §  Company preparing Phase 2/3 clinical trial to support Emergency Use Authorizations §  Company to host conference call today at 9:15am ET to discuss the positive Phase 2 trial results §  Company to make a corporate presentation for Emerging Growth Conference today at 3:00pm ET New York, NEW YORK, and Tel Aviv, ISRAEL, Jan. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease theranostic joint venture partner NLC Pharma Ltd., today announced positive interim data for its Tollovir™ oral antiviral 3CL protease inhibitor Phase 2 clinical trial for the treatment of hospitalized (severe and critical) COVID-19 patients. Tollovir met its primary endpoint of reducing time to clinical improvement as measured by the National Emergency Warning System 2 (NEWS2) and met several key secondary clinical endpoints, including complete reduction in COVID-19 deaths. The Company has now formally closed the Phase 2 clinical trial due to positive interim efficacy data. Lead clinical site Shaare Zedek Medical Center now permits the use of Tollovir™ in hospitalized COVID-19 patients on a compassionate use basis. The Company will host a conference call at 9:15am Eastern Time. The conference call link is: https://audience.mysequire.com/webinar-view?webinar_id=cd68df03-4911-4ded-a910-ba73d61afeeb. The Company will also be presenting at Emerging Growth Conference at 3:00pm Eastern Time. The link to the presentation is: https://goto.webcasts.com/starthere.jsp?ei=1526304&tp_key=6e03917339 “It is extremely exciting to see the validation of Tollovir in a placebo-controlled trial which now allows us to continue on the clinical and regulatory path...